Fibrobiologics Inc
FBLG0.622USD
-0.027-4.18%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
25.40MCap. mercado
PérdidaP/E TTM
Más Datos de Fibrobiologics Inc Compañía
FibroBiologics, Inc. is a cell therapy regenerative medicine company. The Company is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). The Company is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat Multiple sclerosis (MS) and has completed the Phase I study. The Company is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing.
Información de la empresa
Símbolo de cotizaciónFBLG
Nombre de la empresaFibrobiologics Inc
Fecha de salida a bolsaJan 31, 2024
Director ejecutivoMr. Pete O'Heeron
Número de empleados13
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 31
Dirección455 E. Medical Center Blvd
CiudadHOUSTON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal77598
Teléfono12816715150
Sitio Webhttps://fibrobiologics.com/
Símbolo de cotizaciónFBLG
Fecha de salida a bolsaJan 31, 2024
Director ejecutivoMr. Pete O'Heeron
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Hamid Khoja, Ph.D.
Dr. Hamid Khoja, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
31.25K
+177.78%
Dr. Victoria Niklas, M.D.
Dr. Victoria Niklas, M.D.
Independent Director
Independent Director
7.50K
--
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Director
Director
7.50K
--
Mr. Nic Johnson
Mr. Nic Johnson
IR Contact Officer
IR Contact Officer
--
--
Mr. Ruben Garcia
Mr. Ruben Garcia
General Counsel
General Counsel
--
--
Mr. Pete O'Heeron
Mr. Pete O'Heeron
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
--
--
Mr. Richard Cilento, Jr.
Mr. Richard Cilento, Jr.
Independent Director
Independent Director
--
--
Ms. Stacy Coen
Ms. Stacy Coen
Independent Director
Independent Director
--
--
Mr. Matthew Link
Mr. Matthew Link
Independent Director
Independent Director
--
--
Mr. Jason D. Davis
Mr. Jason D. Davis
Chief Financial Officer
Chief Financial Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Hamid Khoja, Ph.D.
Dr. Hamid Khoja, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
31.25K
+177.78%
Dr. Victoria Niklas, M.D.
Dr. Victoria Niklas, M.D.
Independent Director
Independent Director
7.50K
--
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Director
Director
7.50K
--
Mr. Nic Johnson
Mr. Nic Johnson
IR Contact Officer
IR Contact Officer
--
--
Mr. Ruben Garcia
Mr. Ruben Garcia
General Counsel
General Counsel
--
--
Mr. Pete O'Heeron
Mr. Pete O'Heeron
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: lun., 28 de jul
Actualizado: lun., 28 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
O'Heeron (Peter)
14.10%
Golden Knight Inc LP
5.10%
BlackRock Institutional Trust Company, N.A.
3.90%
The Vanguard Group, Inc.
3.39%
Geode Capital Management, L.L.C.
1.47%
Other
72.05%
Accionistas
Accionistas
Proporción
O'Heeron (Peter)
14.10%
Golden Knight Inc LP
5.10%
BlackRock Institutional Trust Company, N.A.
3.90%
The Vanguard Group, Inc.
3.39%
Geode Capital Management, L.L.C.
1.47%
Other
72.05%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
15.84%
Investment Advisor
11.61%
Corporation
5.58%
Investment Advisor/Hedge Fund
4.21%
Research Firm
0.60%
Hedge Fund
0.18%
Bank and Trust
0.07%
Venture Capital
0.05%
Pension Fund
0.03%
Other
61.83%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
123
14.61M
38.17%
+89.36K
2025Q1
124
14.64M
40.12%
+123.60K
2024Q4
115
14.16M
40.30%
-9.06K
2024Q3
108
15.43M
44.70%
+1.86M
2024Q2
83
13.39M
40.93%
+2.95M
2024Q1
29
10.41M
31.81%
+483.30K
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
O'Heeron (Peter)
5.91M
15.44%
--
--
Apr 21, 2025
Golden Knight Inc LP
2.13M
5.58%
+9.85K
+0.46%
Apr 21, 2025
BlackRock Institutional Trust Company, N.A.
1.63M
4.27%
-25.68K
-1.55%
Mar 31, 2025
The Vanguard Group, Inc.
1.42M
3.71%
+508.69K
+55.79%
Mar 31, 2025
Geode Capital Management, L.L.C.
614.64K
1.61%
+9.71K
+1.61%
Mar 31, 2025
State Street Global Advisors (US)
566.45K
1.48%
-8.07K
-1.40%
Mar 31, 2025
Cascade Financial Partners, LLC
260.08K
0.68%
-22.52K
-7.97%
Mar 31, 2025
Northern Trust Investments, Inc.
201.64K
0.53%
-13.77K
-6.39%
Mar 31, 2025
UBS Financial Services, Inc.
112.86K
0.29%
-15.33K
-11.96%
Mar 31, 2025
Optivise Advisory Services, LLC
110.10K
0.29%
--
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Russell 2000 Growth ETF
0%
ProShares Hedge Replication ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
Texas Capital Texas Small Cap Equity Index ETF
0%
iShares Russell 2000 ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 Growth ETF
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
Global X Russell 2000 ETF
Proporción0%
ProShares UltraPro Russell2000
Proporción0%
Proshares Ultra Russell 2000
Proporción0%
Texas Capital Texas Small Cap Equity Index ETF
Proporción0%
iShares Russell 2000 ETF
Proporción0%
iShares Micro-Cap ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
